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Abstract
RET is a mammalian receptor tyrosine kinase required for proper kidney and
neuronal development. RET is expressed as three splice variants named RET9, RET43
and RET51 based on the splice variations at the 3’ end of the gene. All three splice
variants of RET are activated by a complex of proteins including a ligand (GFL) and a
co-receptor (GFRal-4). Although there has been a great deal of work looking at the
early stages of RET activation, less is known about the long-term effects, including
transcriptional changes that occur in response to RET activation. In this study,
transcriptional changes following RET activation were analyzed, paying particular
attention to RET, GFRoc2, RET9 and RET51. The expression levels of RET and GFRa2
were studied using chemilumenescent northern blotting and Quantitative PCR on
neuronal cells responsive to GDNF. For analysis of the splice variants, specific primers
were designed and RT-PCR was run on RNA isolated from the same cells used
previously after the cells were treated with the RET ligand for 0-72 hours. In response to
ligand, there was an increase in the levels of RET9 compared to RET51 or to a control
gene. This increase was seen at 24 hours and increased up to 72 hours after receptor
activation.
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Introduction
RET Background
Receptor tyrosine kinases are a diverse family of receptors containing a single
transmembrane domain and an intracellular tyrosine kinase catalytic domain (Gomperts
et al. 2004). Receptor tyrosine kinases can be activated by peptide ligands, leading to
protein dimerization, transphosphorylation, and association with signaling molecules
(Gomperts et al. 2004). Receptor tyrosine kinases are highly evolutionarily conserved
and found in a multitude of species. While they are absent from the “lower” eukaryotes,
such as yeast, they are present in many other “lower” metazoans and predate the
Cambrian explosion (Arkinstall et al. 1995; Skorohod et al. 1999). While the receptor
tyrosine kinase family is large and varied, all members of this family show certain
features, like a cytoplasmic tyrosine kinase domain and a transmembrane domain
(Gomperts et al. 2004). Generally, receptor tyrosine kinases phosphorylate other
proteins, making them active in a multitude of pathways. These pathways include cellto-cell and cell-to-matrix interactions, activation of B lymphocytes, and the stimulation of
the respiratory burst in phagocytic cells (Gomperts et al. 2004).
RET is a mammalian receptor tyrosine kinase originally identified in a cell
transformation assay looking for cancer causing genes (Takahashi et al. 1985). This
rearranged version of RET contained the cytoplasmic domain fused to a dimerization
domain, leading to constitutive activation of the enzyme. It was not until the proto
oncogene was isolated that the actual receptor was determined. Specifically, RET
consists of two functional regions: the extracellular ligand binding domain and the
cytoplasmic tyrosine kinase domain (Anders et al. 2001). Contained in the cytoplasmic
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domain are five phosphotyrosine residues, pY918, pY905, pY1015, pY1062, and pY1096
(Manie et al. 2001). When the protein is activated adaptor proteins bind to these
phosphotyrosines and trigger a cascade of signals. Specifically, pY918 binds to Src,
pY905 binds to Grb7 and 10, pY1015 binds to PLCy, and pY1096 binds to Grb2 (Manie
et al. 2001 ; Jain et al. 2005). Although all of these phosphorylation sites may play a role
in RET function, pY 1062 has been studied in the most detail. PY1062 binds to the
adaptor proteins Enigma, IRS1, FRS2, and She (Manie et al. 2001). The binding of these
adaptor proteins initiates a cascade of pathways including PKC, PI3-K, JNK, AKT, and
Ras/MAPK (Manie et al. 2001). These pathways play a large role in many processes
including cell survival, migration, differentiation, and proliferation. In fact, mutations in
pY1062 have created the greatest disruption in RET signaling (Jain et al. 2005).
Functionally, RET plays a major role in kidney morphogenesis, neuron survival
and differentiation, sperm cell development, and the development of the enteric nervous
system (Scott et al. 2001). Under normal conditions, the extracellular region of RET
forms a multiprotein complex with a Glial cell-line Derived Neurotrophic Factor (GDNF)
ligand family molecule and a GDNF family receptor alpha 1-4 (GFRal-a4). In this
multiprotein complex, RET is the receptor and GFRocl-oc4 is the co-receptor which
dictates the ligand specificity of this complex (Borrello et al. 2002). The interaction of
this multicomponent receptor complex causes the phosphorylation of the intracellular
domain. The phosphorylation of tyrosine 1062 activates a multitude of signaling
pathways including the MAPK pathway. Recent evidence suggests that the critical
signaling is activated through the autophosphorylation of tyrosine 1062 (Hayashi et al.
2000).
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RET and Disease
Although RET is required for normal cellular signaling, mutations in RET are
known to disrupt cell function. Hirschsprung disease is caused by inactivating mutations
of RET, such as deletions, insertions and point mutations found throughout the protein
(Hansford and Mulligan 2000). Hirschsprung disease causes regions of the intestines to
develop incorrectly and affect 1 in 5000 individuals (Hansford and Mulligan 2000).
Multiple Endocrine Neoplasia Type 2A (MEN2A) is an activating mutation caused by a
substitution in one of many cysteine residues (Hansford and Mulligan 2000). These
substitutions can occur in codons 609, 611,618, 620 or 634, resulting in the disruption of
intramolecular disulfide bridges important in the tertiary structure of RET (Hansford and
Mulligan 2000). The unpaired cysteines then bond inter-molecularly with another RET
molecule causing permanent dimerization and constitutive activation (Hansford and
Mulligan 2000). These constitutively dimerized receptors then lead to neoplasia,
medullary thyroid carcinoma, and papillary thyroid carcinoma (Pasini et al. 1996). In
contrast to extracellular domain mutations, mutations in the tyrosine kinase domain can
result in multiple endocrine neoplasia 2B (MEN2B) (Takahashi 2001). Multiple
Endocrine Neoplasia 2B is caused by a mutation in codon 918 of ret and is associated
with medullary thyroid carcinoma, mucosal neuromas, pheochromocytoma and
ganglioneuromatosis of the digestive tract (Rossel et al. 1997). This mutation causes a
cytosine to take the place of a thymidine, changing the amino acid from a methionine to a
threonine (Hofstra et al. 1994). This mutation has been found in more than 90% of cases
of MEN2B. Because amino acid 918 is found in the substrate binding pocket of RET, the
substitution of a smaller polar threonine for a larger nonpolar methionine is thought to
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change the rate at which RET autophosphorylates, or change its specificity (Carlson et al.
1994; Hansford and Mulligan 2000). This mutation lies between two amino acid
sequences that are highly conserved through all tyrosine kinase receptors, and the
mutation seems to cause the proteins to recognize substrates normally phosphorylated by
cytoplasmic tyrosine kinases (Hansford and Mulligan 2000).
RET Activation
While mutations in RET have been studied since shortly after its initial isolation
the normal activation of RET was not determined until 1996. GDNF was first isolated in
1993 and identified as a member of the Transforming Growth Factor (TGF)-(3
superfamily, also know as the cysteine knot superfamily (Lin et al. 1993). GDNF is a
neurotrophic factor that enhances the survival of midbrain dopaminergic neurons (Lin et
al. 1993). Organisms born without GDNF expression do not develop a normal brain or
intestinal systems, and are born dead or die shortly after birth (Granholm et al. 2000).
GDNF interacts with a member of the GFRa family in order to activate RET signaling.
The GFRa family is made up of four different proteins anchored to the cell membrane
through glycosyl-phosphatidylinositol (GPI) connections (Manie et al. 2001). Each of
these are generally specific to one member of the GDNF ligand family; GDNF, neurturin
(NTN), persephin (PSP), or artemin (ART) (Eketjall et al. 1999), although overlap has
been seen in the ligand binding properties of these co-receptors (Scott and Ibanez 2001).
Splice Variants of RET
It is estimated that up to 60% of human genes have splicing variants produced
through alternative splicing (Faustino and Cooper 2003), and several splicing variants of
RET have been identified (Tsui-Pierchala et al. 2002). Alternative splicing plays an
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important role in many different processes, such as axon guidance, apoptosis and sex
determination (Black 2003). In these cases a pre-mRNA can be spliced in many different
configurations, resulting in many different mRNAs and proteins from a single gene.
Alternative splicing can occur by: deletion of exons, inclusion of extra exons, and
inclusion of intron sequence (Black 2003). In the majority of cases, most exons are
spliced into the final mRNA product. These are called constitutive exons. In other cases,
some exons, called cassette exons, are only included under particular circumstances
(Black 2003). Sometimes, in a process called intron retention, an intron is kept in the
final sequence (Black 2003). The deletion or inclusion of extra sequence can result in
shifting reading frames, extra termination codes, or a change in the amino acids coded for
by the mRNA, resulting in many different proteins (Faustino and Cooper 2003).
Alternative splicing is a process that contributes to the diversity of the proteome, as some
pre-mRNAs can have thousands of splicing patterns (Black 2003). Splicing is carried
out by a complex called the splicesome, which is made up of five small nuclear
ribonucleoproteins (snRNPs) and some accessory proteins (Black 2003). This complex
recognizes a GU dinucleotide at the 5’ end of the intron. This GU dinucleotide is
conserved throughout introns as are three elements at the 3’ end of the intron, a branching
point, a polypyrimidine tract, and an AG, which is located at the 3’ termination of the
intron. Together with the spliceosome these conserved regions work together to splice
the intron out of the pre-mRNA (Black 2003). The most widely accepted theory of
alternative splicing states the change in the splicing pattern seems to be controlled by a
change in the binding patterns of the spliceosome components to the pre-mRNA (Black
2003).
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There are three known splicing variants of RET: RET9, RET51, and RET43. The
first 19 exons of all of these variants are the same. From the C-terminus of the nineteenth
exon, RET9 has nine distinct amino acids, RET51 fifty-one amino acids, and RET43
forty-three amino acids (Tsui-Pierchala et al. 2002). These proteins are produced by the
following splicing variations: the C terminus of exon 19 is spliced to exon 20 in RET51,
the C terminus of exon 19 is spliced to exon 21 in RET43, and in RET9 sequence from
intron 19 codes for the final nine amino acids (Carter et al. 2001).
The splice site for each of these variants occurs at tyrosine 1062, which is noted
as the binding site for many proteins. The variations in splicing change the amino acids
immediately following the tyrosine, altering the binding site considerably since the amino
acids on both sides of the binding site are important for protein recognition of that site
(van der Geer et al. 1996). Tyrosine 1062 is the binding site of the She adaptor protein,
which has two binding domains the phosphotyrosine binding domain (PTB) and the Src
homology 2 domain (SH2) (Ishiguro et al. 1999). These domains have different
consensus sequences for binding. The consensus sequence for PTB binding is N-P-X-pY
which is located N-terminally of tyrosine 1062, and the consensus sequence for SH2
binding is pY-(I/E/Y/L)-X-(I/L/M), which is located C-terminally of tyrosine 1062
(Ishiguro et al. 1999). While RET51 contains only the consensus sequence for the PTB
domain, RET9 contains the sequences to allow binding of both domains (Ishiguro et al.
1999). Changing this binding site would change the cascade pathway started by RET
phosphorylation. The alternative splicing of RET9 and RET51 is evolutionarily
conserved through mouse, rat, horse, chicken, Xenopus, green pufferfish, and Drosophila
(Carter et al. 2001). In RET43 there is little evolutionary conservation, with only a 33%
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identity between rat and human RET43 (Carter et al. 2001). In mouse an area that
appears to be exon 21, the exon coding for the final 43 amino acids of RET43, has been
found however, it also shows only about a 41% homology with humans (Carter et al.
2001). This putative exon does have the amino acids to create the proper SH2 binding
site at tyrosine 1062, but the transcript has not been found in either rat or mouse kidney
tissue (Carter et al. 2001).
Experiments looking at the expression levels of all three proteins in mouse have
shown higher expression levels of RET9 than of RET51 in all tissues through all
developmental stages (Lee et al. 2003). RET43 is expressed in very low levels in humans
in the early weeks of kidney development, but is not thought to play as large a role as
either RET9 or RET51 (Lee et al. 2003). RET is important in the development of the
kidneys and the enteric nervous system, and Wong et al. (2005) have found that RET9
plays a larger part in this development than RET51. Mice that do not have RET9 are
terminal and cannot be saved by expression of RET51, while mice expressing only RET9
develop normally (de Graaf et al. 2001). Scott et al. (2005) concluded that RET51 is a
hypomorphic allele. The alternative splicing that occurs at tyrosine 1062 creates a
binding site on RET9 that binds the SHC protein’s SH2 or PTB domain, whereas RET51
can only bind the PTB domain (Arighi et al. 1997). The tyrosine 1062 binding site is
thought to be the reason RET9 plays such a large role in kidney and enteric nervous
system development. However, the nature of this role the binding site plays remains
unknown, since changing the tyrosine 1062 binding site in RET51 to match that in RET9
does not save the phenotype (Wong et al. 2005).
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There is evidence that RET51 plays a large role in human kidney development
after 8.5 weeks of kidney development (Ivanchuk et al. 1998). This contradicts the
classification of RET51 as a hypomorphic allele (Scott et al. 2005). In the earlier stages
of development, RET9 is expressed in much higher levels when compared to RET51,
however later in development RET51 levels increase sevenfold (Ivanchuk et al. 1998).
This increase in RET51 coincides with the period in gestation in which the minor and
major calyces and the renal pelvis differentiates from the ureteric bud (Ivanchuk et al.
1998). While RET9 may have a larger role in the earlier development of the kidneys and
enteric system, RET51 may play a role in later development, which can implicate the
gene in Hirschsprung’s disease (HSCR). In HSCR the kidneys and enteric system do
develop, but not fully. Families having HSCR have been found to have a missense
mutation in RET51 that did not affect the other isoforms (Attie et al. 1995). With respect
to activating RET mutations, RET9 and RET51 play very different roles in MEN2N.
Specifically, RET51 MEN2B is a strong inducer of neuronal differentiation in PC 12 cells
while RET9 MEN2B has been shown to be a weak inducer (Rossel et al. 1997).
While all three splicing variants retain phosphotyrosine 1062, only RET51 has
additional phosphotyrosine sites, phosphotyrosine 1090 and phosphotyrosine 1096
(Myers et al. 1995). Through phosphotyrosines 1090 and 1096 RET51 interacts with the
SH2 domain of the Grb2 protein. This interaction does not occur in RET9 or RET43 as
both lack the proper binding sites (Lorenzo et al. 1997). While the phosphotyrosines are
important for phosphorylation, the amino acids around them are what cause the
specificity in their binding sites. For She PTB domain interaction non-polar residues
found five to six amino acids N terminal to phosphotyrosine 1062 play an important role
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in binding. These amino acids are the same in all three splicing variants (Lorenzo et al.
1997). However, the important amino acids for the binding of the She SH2 domain are
found C terminally of phosphotyrosine 1062. These amino acids are changed in the
splicing variants through differential splicing (Lorenzo et al. 1997). The amino acids
found C-terminal of phosphotyrosine 1062 in RET9 are found to greatly facilitate the
binding of the She SH2 domain, while those found in RET51 do not, leading to a strong
interaction with RET9 that RET51 lacks (Lorenzo et al 1997).
One of the proteins that bind to phosphotyrosine 1062 is Cbl ubiquitin ligase
(Scott et al. 2005). Cbl proteins are E3 enzymes in the ubiquitylation pathway, E3
enzymes select and recruit proteins that are targets for ubiquitylation (Scott et al. 2005).
In RET, after tyrosine 1062 is phosphorylated, She is phosphorylated and then binds the
Grb2-Cbl complex (Scott et al. 2005). This is a novel approach for Cbl binding, as it
normally binds to proteins through its TKB domain (Scott et al. 2005). It has been found
that Cbl binds to RET51 much better than it binds to RET9, ubiquinating it more often
(Scott et al. 2005). The better binding efficiency in RET51 seems to be attributed to the
fact that Cbl can also interact with RET51 at phosphotyrosine 1096, an amino acid not
present in RET9. When this tyrosine is phosphorylated it interacts with the SH2 domain
of the Grb2-Cbl complex (Scott et al 2005). It is possible that the hypomorphism
RET51 displays early in development may be due to it being a better binding substrate
for Cbl than RET9 and therefore more efficiently downregulated early in development
(Scott et al. 2005).
Measurement of RET Transcription

9

Two important methods for measuring transcription levels are northern blotting
and quantitative Polymerase Chain Reaction (PCR). Both of these methods can be used
to measure RNA levels, but quantitative PCR is more sensitive than northern blotting.
Northern blotting has advantages over quantitative PCR as it provides information on
mRNA size and state as well as expression levels (Bustin 2000). Northern blotting can
either be performed with radioactive or chemiluminescent probes. Quantitative PCR only
provides information on RNA expression levels, but does so in a much more sensitive
manner (Bustin 2000). There are many methods of using quantitative PCR to find
information about RNA expression levels, such as molecular beacons and DNA-binding
dyes (Bustin 2000). One commonly used DNA-binding dye is SyBr Green. SyBr Green
is a fluorescent dye that expresses more fluorescence when incorporated into double
stranded DNA (Bustin 2000). As PCR progresses and more dsDNA is made, SyBr Green
is incorporated into that dsDNA (Bustin 2000). As the dsDNA is amplified the signal
produced by SyBr Green is also amplified, until the amount of fluorescence is crosses an
arbitrary point chosen for that experiment. This point is chosen by the machine based on
the amount of fluorescence already present in the samples, and is used for all samples
being measured at that time (Bustin 2000). The cycle number at which the fluorescence
crosses this threshold is called the Ct, or threshold cycle. Very simply, the higher the Ct
value the lower the amount of cDNA in the sample. The cDNA in the sample directly
correlates to the amount of RNA originally added, and to the amount of RNA originally
purified from the sample (Bustin 2000). This means the lower the Ct value the higher the
expression of that gene. This Ct value can be mathematically converted into an RNA

10

expression level for each sample. The research described here attempts to study the
transcription levels of the RET splicing variants using quantitative PCR.
Materials and Methods
I. Preparation of probes
a. Probes
Expression plasmids containing human RET51 and human GFRot-2 had been
constructed previously. GAPDH was isolated through an RT-PCR reaction using primed
purchased from Stratagene (California, USA) for amplification. For both RET and
GFRa2 probes, the plasmids were digested with the Bgl II restriction enzyme and the
digests run on an agarose gel. For GAPDH, the final PCR product was separated on an
agarose gel after amplification. Two RET fragments (predicted 260 bp and 490 bp), and
a GFRoc2 fragment (predicted 243 bp) were isolated from the gel and the fragments
purified using a DNA extraction kit (Qiagen California, USA) following the
manufacturer’s instructions. The desired bands were cut out of the agarose gel and the
samples were weighed. From here on 1 mg of gel will equal 1 pL of solution. Three
volumes of buffer QG were added to 1 volume of gel and incubated at 50°C for 10 min,
or until the gel was completely dissolved. When the color of the mixture was no longer
yellow 10 pL of 3M sodium acetate was added. One volume of isopropanol was added to
the sample and mixed, the sample was added to the spin column, centrifuged at 14,000
rpm for 1 min, and the flow through discarded. The maximum volume of the spin
column was 800 pL, if the sample was larger it had to be split between spin columns.
Five hundred pL of QG buffer was added and the sample was spun for 1 min, 0.75 mL of
buffer PE was added, the sample was spun for 1 min, and the flow through was

11

discarded. The sample was spun for 1 min and the collection tube and flow through were
discarded. Fifty pL of sterile water were added to the center of the column, the sample
sat for 1 min and centrifuged for 1 min. The resulting DNA was split into 10 pL aliquots.
Once the fragment was isolated and purified, the sample was biotinylated by using
Ambion’s biotinylation system. A clean 0.5 mL microcentrifuge tube was placed on ice.
DNA samples not in TE were placed in a 1 mM EDTA solution and 5-100 ng of DNA
were heated in a microcentrifuge tube for at least 10 min at 100°C. The samples were
placed in an ice-water bath until completely cooled and all unnecessary lights were
turned off. One pL of prepared BrightStar Psoralen Biotin was added for every 10 pL of
DNA, mixed and transferred to the microcentrifuge tube on ice. Samples were irradiated
with a 365 nm UV light placed 3 cm directly above sample for 45 min. Once the
irradiation process was completed, the lights were turned back on. The sample was
diluted to 100 pL by adding 89 pL of TE Buffer and transferred to a clean
microcentrifuge tube. Two hundred pL of well shaken water saturated n-Butanol was
added to the sample. The mixture was vortexed, spun at 7,000xg and the top layer was
removed with a pipette. The addition and extraction of the butanol was done once more
and the probe was split into 10 pL aliquots and placed at -80°C freezer.
b. Qiagen Miniprep
Fifteen hundred mL of an overnight bacterial sample was placed into 1.5 mL
microcentrifuge tubes. The samples were centrifuged at 14,000 rpm for 5 min. The
supernatant was poured off and the samples were centrifuged for 30 sec at 14,000 rpm.
The pellets were resuspended using 250 pL Buffer PI and a vortex. Two hundred and
fifty pL Buffer P2 were added and the tubes were inverted four to six times. Three
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hundred and fifty mL of Buffer N3 was added and the tubes were again inverted four to
six times. The samples were centrifuged for 10 min at 14,000 rpm and the supernatant
transferred to a spin column placed in a 2 mL collection tube. The spin column and
collection tube were centrifuged at 14,000 rpm for thirty to sixty sec and the flow through
was discarded. Seven hundred and fifty pL Buffer PE was added to the spin column and
centrifuged for 30-60 sec and the flow through discarded, centrifuged for one min and the
collection tube with the flow through discarded. The spin column was placed in a new
1.5 mL microcentrifuge tube and 50 pL sterile water was placed in the center of the spin
column. After 1 min the column was centrifuged for 1 min and the flow through
containing the plasmid was saved.
c. Ethanol Precipitation
The digests were heated to 70°C for 5-10 min inactivate the enzymes. Two Vol
100% ethanol were added, followed by 0.1 Vol of 3M Sodium Acetate, pH 5.2. The
samples were incubated at -20°C at least overnight and centrifuged for 10 min at 14,000
rpm. The supernatant was removed, the samples were spun for 30 sec at 14,000 rpm, the
supernatant was removed, and the desired volume of water was added (Ausubel et al.
1990).
d. Transformation
One pL plasmid was added to 100 pL of competent DH5a E. coli cells. The
mixture was iced for 15 min, heat shocked at 42°C for 90 sec, and iced for 2 min. The
mixture was plated on 50 pg/mL LB/Ampicillin plates (LB contents: agar, Sodium
Chloride, yeast extract and pancreatic digest of Casein) and grown overnight at 37°C
(Ausubel et al. 1990).
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e. Agarose Gels
DNA was run on 1% TAE agarose gels were made with 0.5 g of agarose per 50
mL of IX TAE. The gels were run in IX TAE with 5 |LiL of ethidium bromide at 100
Volts.
f. Restriction Digest
Fifteen pL sterile water, 2 pL DNA, 1 pL Bgl II (Promega Wisconsin, USA), and
2 pL 10X buffer H (Promega) were placed in a microcentrifuge tube and incubated at
37°C for one and a half hours.
II. Isolation of RNA
a. Treatment of Cells
SK-N-SH cells were obtained from the American Type Culture Collection (ATCC
Virginia, USA). LAN-5 cells were obtained from C. Worby (Lab of Dr. Jack Dixon UCSan Diego). Both cell lines were grown in media and kept in a CO2 rich environment at
37°C. The cells were treated over a variety of time points with 1 pL 0.1 mg/mL GDNF
(Promega), Retinoic Acid (Sigma Missouri, USA), Sodium Butyrate (Sigma), or GDNF
in combination with Retinoic Acid.
b. RNA Purification
RNA from treated cells was purified using the Stratagene (California, USA) kit.
Cells were aspirated and 600 pL lysis buffer and 4.2 pL p-mercaptoethanol were added.
The cell lysate was collected and mixed through repeated pipetting and transferred to a
microcentrifuge tube and vortexed. From this point on the lysate/RNA was kept on ice.
The lysate was passed through a 25 gauge syringe five to six times, 700 pL was
transferred into the prefilter spin cup and centrifuged at 14,000 rpm for five min. The
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spin cup was removed, discarded and 700 pL of 70% ethanol was added to the flow
through. The ethanol and flowthrough were vortexed. Seven hundred pL of this mixture
was transferred to an RNA Binding Spin cup and centrifuged at 14,000 rpm for 30-60
sec. The filtrate was discarded, 600 pL of IX High Salt Wash was added to the spin cup
and was centrifuged for 2 min at 14,000 rpm. The filtrate was discarded and the spin cup
was placed in a new collection tube, and 300 pL of IX Low Salt Buffer was added to the
spin cup. The spin cup assembly was centrifuged for two min at 14,000 rpm and
transferred to a clean RNase free 1.5 mL microcentrifuge tube. Thirty pL of Elution
Buffer (contents proprietary) was added to the center of the spin cup, incubated for two
min at room temperature, and centrifuged at 14,000 rpm for two min. The RNA was
divided into 10 pL aliquots and stored at -80°C.
III. The Northern Blot
a. Glyoxyl Gel
All equipment used was treated with Ambion’s (Texas, USA) RNase Zap™ to
destroy surface RNases. The glyoxyl gel was run following Ambion’s glyoxyl gel kit.
One gram of RNase free agarose was melted in a 1:10 mixture of 10X Gel Prep/Gel
Running Buffer (contents proprietary) and RNase free water. 10X Gel Prep/Gel Running
Buffer was diluted to IX and poured into the gel box. The purified RNA was mixed with
an equal amount of glyoxyl loading dye and loaded into the gel wells. Ambion’s
Millenium Marker™ was mixed with an equal amount of glyoxyl loading dye and loaded
into a well. Five pL of ethidium bromide was added to the buffer and the gel was run at
100 Volts for 45 min. The gel was viewed on a UV transilluminator using the Kodak
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Image Station (Kodak New York, USA). The transilluminator was wrapped in RNase
free plastic wrap.
b. Transfer
The transfer procedure was performed according to Ambion’s glyoxyl gel kit.
The unused parts of the glyoxyl gel were removed and a Brightstar-Plus™ membrane
was cut to the same size as the gel, this membrane was handled by the edges using nonpowdered gloves or blunt forceps. Eight sheets of filter paper and a 3 cm stack of paper
towels were cut slightly larger than the membrane and the gel. Half of a mL per cm“ of
gel of transfer buffer was placed into a flat bottomed container a little larger than the
membrane and gel. Three filter paper bridges were cut large enough to cover the gel and
connect to the container holding the transfer buffer. The transfer materials were
assembled as follows from the bottom up: 3 cm of paper towels, 3 dry pieces of filter
paper, 2 wet pieces of filter paper, the membrane, the gel, 3 dry pieces of filter paper, the
filter paper bridge and a cover weighing between 150 and 200 grams. After each layer
was put down the air bubbles were rolled out with a stirring rod, the filter paper bridge
was put in contact with the transfer buffer in the container and the apparatus was left to
transfer for one and a half to two hours. The transfer set-up was found in Current
Protocols in Molecular Biology (Ausubel et al. 1990). The gel was checked for ethidium
bromide, the membrane was removed with blunt forceps, and rinsed with IX gel running
buffer. Excess moisture was blotted off the membrane, but the membrane was not dried.
The membrane was crosslinked immediately by baking for 15 min at 80°C and stored
until use at -20°C in a 50 mL conical tube.
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c. Prehybridization and Hybridization
Ambion’s ULTRAhyb™ was preheated to 68°C. Ten mL per 100 cm2 of
membrane was placed with the membrane for at least 30 min at 42°C. Enough probe to
bring the final concentration of the ULTRAhyb™ to 1.0-10 pM was denatured by
diluting it 10-fold with 10 mM EDTA, incubating it at 90°C for 10 min and centrifuging
it briefly. Half of a mL of ULTRAhyb™ was added to the denatured probe and
transferred to the roller bottle containing the prehybridized blot. The membrane was
hybridized for between 14 and 24 hours.
d. Detection
Immediately following hybridization the membrane was washed twice with
agitation for 5 min using 20 mL per 100 cm2 membrane with Low Stringency Wash
Solution #1 (2X SCC). Two more washes were done using 20 mL per 100 cm2
membrane of High Stringency Wash Solution #2 (0.1X SCC), these washes were at 42°C
with agitation for 15 min each. Each of the following incubations was at room
temperature with gentle agitation in containers that allowed for free movement of the
membrane: 2 five min washes in 1 mL IX Wash Buffer/cm2 membrane/wash; 2 five min
washes in 0.5 mL Blocking Buffer(contents proprietary)/cm2 membrane/incubation; 1
thirty min wash in 1 mL Blocking Buffer/cm2 membrane; 1 thirty min incubation in 10
mL Blocking Buffer and 1 pL Strep-Alkaline-Phosphatase/100 cm2 membrane; one 10
min incubation in 0.5 mL Blocking Buffer/cm2 membrane; 3 five min washes in 1 mL IX
Wash Buffer/cm2 membrane/wash; 2 two min incubations in 0.5 mL IX Assay
Buffer/cm2 membrane/incubation; 1 five min incubation in 5 mL CDP-Star/100 cm2
membrane. The excess CDP-Star was blotted off with filter paper without letting the
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membrane dry and the membrane was wrapped in a single layer of plastic and exposed
between 2 and 12 hours.
IV. Controls
a. Probe Dot Blots
Strips of BrightStar-MembranePlus™ were cut and descending concentrations of
the probe were dotted on them. The concentrations were: 1 ng/pL; 100 pg/pL; 10 pg/pL;
1 pg/pL; 100 fg/pL and 10 fg/pL. The membranes were crosslinked for 15 min at 80°C
and put through the detection procedure.
b. RNA Dot Blots
A membrane was dotted with dilutions of control RNA supplied by Ambion. The
membrane was crosslinked for 15 min at 80°C and put through the prehybridization,
hybridization and detection procedures.
V. RT-PCR
a. Design of Primers
All primers were designed by hand. A 300 base pair of the 5’ end of Ret51 was
amplified using the primers forward: 5’-AGGAGAATTGGTAGTAGAAGAGG-3\ and
reverse: 5 ’-CCTACGAAAGTGGGAGTCG-3 ’. A 200 base pair fragment of the 5’ end
of RET9 was amplified using the primers forward: 5’AGAGAGGAGAATTGGTAGTAGAAGA-3’, and reverse: 5’AAGGGT ACGT AAAT GATCTAAG- 3’.
b. Synthesis of cDNA
All primers were originally diluted to 100 pM. One pL of a 1:10 dilution of
RNA, 2 pL of a 1:10 dilution of the 3’ primer, 2 pL of a 1:10 dilution of the 5’ primer, 1
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pL of the dNTP mixture were added to an thin walled 0.2 mL PCR tube, RNase free
water was added to bring the volume to 13 jllL. During the first 4°C plateau 4 pL 5X
Buffer, 1 pL 0.1 M DTT, 1 pL RNase Out™ and 1 pL of a 1:5 dilution of reverse
transcriptase (RT) were added to each tube. For creating the 18S cDNA two pL of
Ambion’s Quantum RNA Universal 18S primer mix were used, and the amount of RNase
free water was raised to keep the final volume to 13 pL.
c. RT-PCR
All primers except the 18S primers were originally diluted to 100 nM. Two pL of
cDNA, 1 pL of a 1:10 dilution of the 3’ primer, 1 pL of a 1:10 dilution of the 5’ primer, 5
pL 10X Buffer, 3 pL MgCl2 and 1 pL 2.5 mM dNTP mixture were added to a .2 mL thin
walled PCR tube, RNase free water was added to bring the final volume to 50 pL. A Taq
bead, containing 1.25 pg of Taq polymerase, was added to the tube and the tube was
placed in the thermocycler. PCR was run under the following conditions: 50°C for 30
min, 95°C for 15 min, and cycled through 95°C, 50°C and 72°C thirty times staying at
each temperature for 1 min during each cycle. Then held then held at 72°C for 10 min
and stored the samples at 4°C until taken out of the machine.
VI. Quantitative (Q) PCR
a. Q-PCR
All except the 18S primers were originally diluted to 100 nM. Two pL cDNA,
12.5 pL SyBr Green, 2 pL of a 1:10 dilution of the 3’ primer and 2 pL of a 1:10 dilution
of the 5’ primer were added to a thin walled .2 pL PCR tube, RNase free water was
added to bring the final volume up to 25 pL. In the 18S samples only 1 pL of a 1:10

19

dilution of Ambion’s (California, USA) 18S prime5 mix was added with RNase free
water used to make up the volume. Negative controls were run using RNase free water in
place of cDNA. The samples were placed in the quantitative thermocycler (Stratagene’s
Mx3000P) and put through the following cycle: 95°C for 10 min, 40 cycles of 95°C for
30 sec, 55°C for 1 min and 72°C for 30 sec.
b. Converting Ct values into RNA Expression Levels
To use the Ct values to find RNA expression levels the AACt formula was used
(Muller et al. 2002).
2-(ACt target)
2-(ACt reference)

The ACt of the target was obtained by subtracting the standard from the unknown. In this
case, the standard was the untreated sample and the unknown as any of the treated
samples. The ACt of the reference was obtained in the same manner (Muller et al. 2002).
The reference was a housekeeping gene, either (3-actin or 18S. The standard deviation for
the AACt was found by taking the standard deviation of the average of the Ct values. The
standard deviation was then added and subtracted from the average, the resulting
numbers were put through the AACt formula, resulting in a high and a low that were
graphed as the standard deviation (Muller et al. 2002).
Results
Although RET activation has been studied in some detail, the results of RET
activation, especially with respect to transcription of the receptor and co-receptor have
not been studied extensively. To study the changes in RET and GFRa2 mRNA levels, a
neuroblastoma cell line known to respond to GDNF (SK-N-SH cells) was treated with the
ligand for increasing amounts of time and the RNA purified (Table 1).
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GDNF Treatment (hrs)
0
24
48
72

A260
0.012
0.019
0.008
0.021

A280
0.008
0.013
0.013
0.014

Concentration
240 pg/mL
380 pg/mL
260 pg/mL
420 pg/mL

A260/A280
1.50
1.46
0.72
1.50

Table 1. RNA absorbance readings, concentrations and A260/A280 ratios for RNA
purified from cells either not treated, or treated with GDNF for increasing amounts of
time. These RNA samples were used for the northern blots and the dot blots.
The RNA was then analyzed for RET and GRFa2 expression using northern analysis.
Prior to performing the northern blot, simple dot blots, in which probe was dotted onto
the membrane, crosslinked and put through the detection procedure, were performed to
confirm that the probes were functional.
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Figure 1. Dot blot of the three probes made for the northern blot. The top is the control
probe supplied by Ambion, the sec lane is unlabeled DNA showing no fluorescence, the
third lane is the GFRa2 probe and the fourth is the Ret probe.
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Figure 2. Dot blot of the GAPDH probe.
Addition of either RET, GFRa2 or GAPDH probe was seen in the initial probe studies,
some probes even gave off brighter signal than the control probe (Figures 1 and 2).
Unfortunately, when the northern blot was probed with either GFRa2 (Figure 3) or (3actin (Figure 4) probes, ladder could be seen but no sample could be identified.

Ladder
72 hr.
48 hr.
24 hr.

'

0 hr.
Figure 3. A northern blot hybridized with the GFRa2 probe. The top lane contains the
ladder. All other lanes contained 10 pL of RNA from cells treated with GDNF for 72
hours, 48 hours, 24 hours, or 0 hours.
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Ladder
Control RNA
*

Figure 4. The control northern blot was hybridized with the p-actin probe. There were
two lanes, one containing the ladder, one containing the control RNA.
To test the reasons for this lack of sample visualization, 1 pg, 100 ng, 10 ng, and 100 pg
of control RNA was spotted onto a membrane directly. This dot blot was then treated
with the P-actin probe and visualized for four and then eight hours (Figures 5 and 6).

Figure 5. Four hour exposure.

Figure 6. Eight hour exposure. Figures 5 and 6 are both a dot blot dotted with 100 pg, 10
ng, 100 ng, and 1 pg of control RNA and probed with the p-actin probe. The dot blot was
then exposure for four hours, and then exposed again for eight hours.
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Although faint, the signaling of the (3-actin probe was evident. The same procedure was
then run with our purified RNA using GAPDH as the probe (Figure 7). It was
hypothesized that if no signal was found from the GAPDH, which should be present in
higher concentrations than Ret or GFRa2, we would not be able to get signal running a
normal Northern Blot. The membrane was exposed for 10 hours and no signal was seen.
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Figure 7. The dot blot was dotted with 100 pg, 10 ng, 100 ng, and 1 pg of RNA purified
from untreated cells and probed with a GAPDH probe.
In a last attempt to make sure that the lack of signal was not simply a problem with the
GAPDH probe, dot blots with RNA were run and Ret and GFRa2 probes were
hybridized, but, as expected, no signal was detected (Figure 7).
Because the northern technique was not successful, another technique,
quantitative (Q) PCR, was used to analyze gene expression. For the initial experiments,
the production of RET or GFRa2 RNA was measured through the taqman system of QPCR. Using the previously designed primers against RET and GFRa2 in a taqman
system, it was determined that there was a slight GDNF-dependent increase in RET but
no significant increase in GFRa2.
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Because of this potential increase in RET expression levels, future experiments
focused on RET transcriptional regulation. Given the importance of RET splice variants,
the levels of RET9 and RET51 were measured from the same RNA samples. 18S
primers were used to normalize the experimental samples. The Ret9 primers were
designed to include the 18 base pairs from intron 19 and for the rest of the product to be
from exon 19. The Ret51 primers were designed to amplify the 153 base pairs from exon
20 with the remaining 147 base pairs from exon 19. Cross-exon primers were used to
reduce the background signal due to DNA contamination.
Prior to performing Q-PCR, the Ret9 and Ret51 primers were used to perform
RT-PCR and the results analyzed by gel electrophoresis in order to determine if RET9
and RET51 are expressed in this cell type. Gel electrophoresis demonstrated that bands
corresponding to both RET9 and RET51 were evident in the RT-PCR reactions
performed on SK-N-SH RNA. These bands were RT-dependent and were of the
expected size for each of the primer sets designed (Figure 8).
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Figure 8. Agarose gel of initial PCR products. Lane 1 is Ret51, lane 2 is the no template
control of Ret51s. Lane 3 was Ret9, lane 4 was the no template control of Ret9. Lane 5
was 18S, lane 6 was the no template control of 18S.
Once the presence of these splice variants was determined, experiments were performed
using RNA-purified from cells treated with GDNF, Retinoic Acid, and sodium butyrate,
treatments that have been implicated in RET expression changes (Table 2).
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Sample
No Treatment
GDNF
Retinoic Acid
Sodium Butyrate
GDNF and Retinoic
Acid

A260
0.270
0.267
0.216
0.249

A280
0.160
0.166
0.133
0.157

Concentration
1.35 pg/mL
1.34 pg/mL
1.08 pg/mL
1.25 pg/mL

A260/A280
1.69
1.61
1.62
1.59

0.322

0.199

1.61 pg/mL

1.62

Table 2. RNA absorbance readings, concentrations and A260/A280 ratios for RNA purified
from cells either not treated, or treated with GDNF, Retinoic Acid, Sodium Butyrate, or
GDNF and Retinoic Acid as shown. Cells were treated for 24 hours prior to RNA
collection.
Using cDNA created from RNA purified from cells treated with GDNF, Retinoic
Acid, Sodium Butyrate and a combination of GDNF and Retinoic Acid a regular PCR
reaction was run using the Ret9 primers, with 5 pL of each reaction taken out at cycles
30, 36, 37, 38, 39 and 40. For each sample except sodium butyrate, the intensity of the
PCR product increased with increasing cycles. These results showed what were thought
to be increasing amounts of PCR product as the cycles continued; however the results are
not clear. Using the untreated RNA samples a similar experiment was run using the
Ret51 primers. Five jlL samples were taken out of the reaction at 10, 20, 25, 30, 35 and
40 cycles. These results showed only a band in the lane containing the sample taken at
40 cycles.
Results have been obtained through all three sets of primers using Quantitative PCR
and RNA purified after being treated with GDNF for different amounts of time (Table 3).
Using the Ct values obtained through Q-PCR we have found the relative expression
levels for Ret9 and Ret51 (Table 4). Relative expression levels were found through use
of the AACt formula. The comparison of these expression levels shows a large change
over time. The expression of Ret9 increases over time as compared to Ret51. At 24
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hours we see a 4.72 fold increase, at 48 hours we see a 6.36 fold increase, and at 72 hours
we see a 12.73 fold increase in Ret9 compared to Ret51 (Figure 9). While the standard
deviation at 24 hours makes that number questionable, it does agree with other data in
which we see a spike of Ret51 at 24 hours.
GDNF Treatment (hrs)
0
0
0
24
24
24
48
48
48
72
72
72

A260
0.009
0.016
0.011
0.021
0.019
0.011
0.009
0.017
0.008
0.008
0.019
0.021

A280
0.003
0.007
0.005
0.010
0.010
0.005
0.001
0.006
0.001
0.002
0.008
0.010

Concentration
.045 pg/mL
.080 pg/mL
.050 pg/mL
.105 pg/mL
.095 pg/mL
.050 pg/mL
.045 pg/mL
.085 pg/mL
.040 pg/mL
.040 pg/mL
.095 pg/mL
.105 pg/mL

A260/A280
3.0
2.3
2.2
2.1
1.9
2.2
9.0
2.8
8.0
4.0
2.4
2.1

Table 3. RNA absorbance readings, concentrations and A260/A280 ratios for RNA purified
from cells either not treated, or treated with GDNF for increasing amounts of time.
These RNA samples were used for the northern blots and the dot blots.
Ret9
NTC
No Treatment
24 hours
48 hours
72 hours
Ret51
NTC
No Treatment
24 hours
48 hours
72 hours

35.49
30.09
29.04
28.14
28.71

No Ct
26.31
28.47
28.06
29.49

33.18
29.21
29.00
29.12
29.32

36.07
27.12
29.37
28.15
29.78

35.25
30.48
31.42
28.17
29.62

Average
34.64
29.93
29.82
28.48
29.22

Std. Dev.
±1.27
±0.65
±1.38
±0.56
±0.46

39.11
27.18
29.15
28.05
30.21

Average
35.06
26.87
29.00
28.09
29.83

Std. Dev.
±5.51
±0.49
±0.47
±0.06
±0.36

Table 4. Ct numbers used to create figure 9.
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R e la tiv e E x p re ssio n L e v e ls (R e t 9 vs. Ret
51)
14
12
10
8

6

4
2

0
Tim e (hrs) A fte r G D N F T re atm e n t

Figure 9. Expression levels of Ret9 relative to Ret51 using the data in Table 1.
Comparison of both Ret9 and Ret51 levels to the levels of a housekeeping gene
results in comparable expression levels for both genes. The Ct values of Ret9, Ret51 and
(3-actin are found in Table 5. These numbers were then converted to expression levels
using the AACt formula, and these numbers graphed (Figure 10). While overall the graph
shows higher expression levels in Ret9, the standard deviations for those samples are
quite high, making these data questionable. To find the source of the large standard
deviation the biological replicates were graphed separately in comparison to p-actin
(Figures 11 and 12). Only the graphs from biological replicate 2 showed the large error
bars, so the error seems to be coming from these samples. Using the same data we once
again compared expression of Ret9 to expression of Ret51 (Figure 13). While these data
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give the same trend as the previous graphs, the standard deviation once again casts doubt
on these results.

40.09
39.02
37.5
36.61

Average
37.56
37.40
37.25
36.49

Std.
Dev.
±1.55
±1.41
±0.94
±0.87

31.5
33.92
31.04
32.32

31.56
31.79
31.36
35.43

31.13
32.01
30.55
32.43

±0.67
±1.12
±0.65
±1.51

25.8
31.14
29.05
30.76

25.7
32.27
28.91
30.68

25.31
31.35
28.07
30.89

±0.43
±0.89
±1.02
±0.41

RNA
Sample
0
24
48
72

Ret9
38.60
38.43
35.62
35.78

37.61
37.39
37.31
37.02

36.74
36.05
36.83
37.23

36.25
38.11
38.08
35.12

36.08
35.41
38.17
37.23

0
24
48
72

Ret51
30.99
31.19
29.72
31.3

30.21
30.99
29.93
31.61

30.55
31.47
30.34
31.78

31.98
32.73
30.9
32.15

0
24
48
72

3-actin
25.17
30.24
27.11
31.25

25.46
30.82
27.27
31.48

24.66
31.04
27.04
30.8

25.06
32.57
29.02
30.34

Table 5. Ct values used to create figures 10-13.
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Ret9 and Ret51 Expression Levels w ith p-actin as
a R eference
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Figure 10. Relative expression levels of Ret9 and Ret51.
Ret9 Exp ression Levels w ith (3-actin as a R eference
(B iological Sam ple #1)
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Figure 11. Relative expression levels of Ret9 and Ret51 for Biological Sample #1.
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Ret9 Ex p re ssion Levels w ith (3-actin as a R eferen ce
(B io lo g ical Sam ple #2)

Figure 12. Relative expression levels of Ret9 and Ret51 for Biological Sample #2.
Ret9 Expression Levels with Ret51 as a R eference

Tim e (hrs) A fte r GDNF T reatm en t

Figure 13.

Expression levels of Ret9 relative to Ret51 using the data in table 2.
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Discussion
RET is a receptor tyrosine kinase used in many pathways necessary in cell
survival, differentiation and proliferation (Jain et al. 2005). It is well known that the
activation of the phosphotyrosines on the cytoplasmic domains activate these pathways,
but little is known about the long term effects of the activation of RET. Understanding
how RET plays a part in these cell processes is important and might help in the treatment
of Hirschsprung disease, MEN2A and MEN2B which are all caused by mutations of RET
(Hansford and Mulligan 2000).
Northern blotting was used to study the expression of RET and its co-receptor,
GFRa2, in neuronal cells over time after treatment with GDNF. We took a
chemiluminescent approach to visualizing the expression levels. Unfortunately, while all
the parts of the system worked we were unable to get a high enough concentration of
RNA to obtain a visible signal in the northern blots or the dot blots. While the
chemiluminescence is a safer system than using radioactivity, it is also less sensitive.
However, radioactivity is much more dangerous than chemiluminescence and northern
blots are not the only way to analyze RNA expression levels. Q-PCR was being used to
analyze other expression levels with success, so the decision was made to switch to that
system.
The receptor tyrosine kinase, RET has three splice variants and has been found to
be instrumental in kidney development and neuronal differentiation. RET9 has been
shown to be more instrumental in kidney development than RET51. Mice mutated to
express only RET51 died, while mice expressing only RET9 developed normally (de
Graaff et al 2001). The degradation of RET51 is more tightly regulated via the
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ubiquinylation pathway through the binding of Cbl at two phosphotyrosine sites, pY 1062
and pY 1096, instead of one as occurs in RET9 (Scott et al. 2005). This implies RET9
plays a larger role in RET signaling. Therefore, cells in which RET signaling is involved
would tend to have more RET9 than RET51. This information leads to the hypothesis
that Ret9 is the more important splicing variant, and therefore would be found in higher
levels following activation with GDNF. The increase in Ret9 expression, and the level of
Ret51 to either decrease or remain stationary is consistent with the previous data.
SK-N-SH cells are neuronal cells that have been found to over express RET, but
had not been previously examined for expression of the RET splicing variants. We found
that both RET9 and RET51 splicing variants were expressed in these cells. Previous
unpublished work has shown a small increase in RET expression after treatment with
GDNF, from there we worked to see if one splicing variant was the cause of this increase.
The expression levels of the splicing variants were examined after treating the cells with
GDNF. In the SK-N-SH cells high levels of Ret9 expression over Ret51 expression
shows that the activation of RET in these cells by GDNF leads to the cell preferentially
choosing one splicing variant over the other, suggesting that Ret9 is more instrumental in
the pathways induced by GDNF treatment than Ret51. The data also demonstrates a
consistent spike in Ret51 levels at 24 hours, but by 72 hours Ret9 seems to have taken
over showing much higher expression levels.
Similar results have been observed in previous studies, where the activation of a
protein leads to preferential splicing of one variant over another. For example, hepatoma
cells express two splicing variants of Interleukin-1 Receptor Accessory Protein (ILlRAcP). The membrane bound variant of this protein, mIL-lRAcP, promotes
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intracellular signaling, and the soluble variant, sIL-lRAcP, is most likely an inhibitor of
signaling by interleukin-1 (Jensen and Whitehead 2003). When the hepatoma cells are
treated by phorbol esters, a 16-fold increase in the mRNA levels of sIL-lRAcP is seen.
(Jensen and Whitehead 2003). In another study, the channels that allow signaling
through the hippocampus are made up of many proteins. One of those proteins,

ocia, has

two splicing variants, (XiA-a and aiA-b (Vigues et al. 1999). Rats treated with kainic acid
to induce seizures and the tissue analyzed for a change in expression of the mRNAs for
these proteins (Vigues et al. 1999). a^-b splice variants show a marked increase in
expression six hours after treatment, and this upregulation lasted for 7 days following
treatment (Vigues et al. 1999).
Splicing regulation calls for a complex of many proteins and is a complicated
process. However, the splice regulation of Ret9 and Ret51 are not the same as Ret51 is
the product of splicing and the choice of exons used, and Ret9 is the product of intron
retention. This changes the competition, where in splicing in Ret51 there is simply
competition between different splice sites for spliceosome assembly, and in Ret9 there is
a competition between the mechanism of splicing and the mechanism that allows for
mRNA transport (Black 2003).
GDNF plays a role in the survival of neurons and has been explored as a possible
cure for Parkinson’s disease (Gill et al. 2003). However, the reason that GDNF has a
positive effect on Parkinson’s patients is not well understood. Part of the reason for this
lack is that there is little known of the effects of RET. Many of the pathways RET
activation initiates are known, but more work needs to be on the long-term effects of
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these pathways. We now see that treating neuronal cells with GDNF causes the cell to
preferentially choose for the RET9 splicing variant over the RET51 splicing variant.
Further work in this area is needed. This data was based on RNA samples taken
from one treatment cycle with biological duplicates. Cells need to be treated over a wider
time period, and consistent results need to be shown. Additionally, the mechanism
needed to change which splice product is produced needs to be studied as well.
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